Fiche publication
Date publication
janvier 2018
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie
,
Pr GHIRINGHELLI François
,
Dr HERVIEU Alice
,
Dr FUMET Jean-David
,
Dr HENNEQUIN Audrey
,
Dr ZANETTA Sylvie
Tous les auteurs :
Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F
Lien Pubmed
Résumé
5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate whether the addition of PD-L1 and CTLA-4 inhibition to oxaliplatin, fluorouracil and leucovorin (FOLFOX) increases treatment efficacy.
Mots clés
chemotherapy, colorectal cancer, durvalumab, immunotherapy, tremelimumab
Référence
ESMO Open. 2018 ;3(4):e000375